Well it looks like I will be receiving loyalty options then....

Well it looks like I will be receiving loyalty options then. With such a short expiry, I am confident BioGene will get them in the money comfortably come December as more testing results come out.

Flavocide is still in its R&D stage but there is room to grow if they are able to leverage their tech with the right partners, both in field testing and manufacturing.

Initial results so far shows it works and more results with Virbac are anticipated. Management here are highly experienced and would not be wasting their time if this pesticide was useless.

To me their granted and pending patent portfolio is worth more than the current market cap, including patents granted in Europe, US, Japan, Australia and NZ for beta-triketone products and their use as insecticides.

A long term play but a huge reward at the end.